Sleep suppressant action of quipazine: relation to central serotonergic stimulation.
Administration of quipazine maleate (1-10 mg/kg, IP), a proposed 5-hydroxytryptamine (5-HT) receptor stimulant to rats produced a dose-related suppression of both slow-wave sleep (SWS) and rapid-eye-movement sleep (REMS) accompanied by an increase in head-shaking behavior. These effects were observed during the first 6 hr of a 12-hr EEG recording session. The latencies to the sleep states were markedly prolonged and correlated with the duration of head-shaking behavior induced by the drug. A significant inverse relationship was found between the amount of SWS or REMS and the number of head-shakes occurring during the first 6-hr period. Since head-shaking behavior in rodents has been proposed as a quantitative, behavioral model of central 5-HT activation, the data suggest a causal relationship between enhanced 5-HT activity and sleep suppression. This assumption is further supported by the observation that pretreatment with metergoline (2.5 mg/kg, IP) a 5-HT receptor blocker, reduced quipazine's effects on both SWS and head-shaking behavior.
D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects; D004569:Electroencephalography; D004576:Electromyography; D005071:Evoked Potentials / Q000187:drug effects; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D011814:Quipazine / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011985:Receptors, Serotonin / Q000187:drug effects*; D012894:Sleep Stages / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects; D014851:Wakefulness / Q000187:drug effects
D011804:Quinolines; D011985:Receptors, Serotonin; D008711:Metergoline; D011814:Quipazine